Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 250Carcinoma, Non-Small-Cell Lung 86Carcinoma, Renal Cell 62Neoplasm Metastasis 53Neoplasms 51Prostatic Neoplasms 35Lung Neoplasms 32Uveal Melanoma 29Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Brain Neoplasms 24Colorectal Neoplasms 23Sarcoma 22Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Kidney Neoplasms 18Skin Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Urinary Bladder Neoplasms 14Triple Negative Breast Neoplasms 14Mesothelioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Recurrence 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

toripalimab 2Oxaliplatin 2tesetaxel 1indusatumab 1Trastuzumab 1S 1 (combination) 1Nivolumab 1Leucovorin 1Ipilimumab 1GC1118 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of the Stomach × Ipilimumab × Clear all
NCT03647969 2024-08-09

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed
262 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

Data powered by HemOnc (CC BY 4.0) Colophon âš¡